Iron deficiency in preschool children with autistic spectrum disorders / Ayhan BILGIC in Research in Autism Spectrum Disorders, 4-4 (October-December 2010)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 4-4 (October-December 2010) . - p.639-644 Titre : Iron deficiency in preschool children with autistic spectrum disorders Type de document : texte imprimé Auteurs : Ayhan BILGIC, Auteur ; C. Kağan GURKAN, Auteur ; Serhat TURKOGLU, Auteur ; Ömer Faruk AKCA, Auteur ; Birim Günay KILIÇ, Auteur ; Runa USLU, Auteur Année de publication : 2010 Article en page(s) : p.639-644 Langues : Anglais (eng) Mots-clés : Iron-deficiency Ferritin Autistic-spectrum-disorders Preschool-children Behavioral-problems Index. décimale : PER Périodiques Résumé : Iron deficiency (ID) cause negative outcomes on psychomotor and behavioral development of infants and young children. Children with autistic spectrum disorders (ASD) are under risk for ID and this condition may increase the severity of psychomotor and behavioral problems, some of which already inherently exist in these children. In the present study, the frequency of ID and the association between ID and autistic symptoms, developmental level, and behavioral problems in preschool children attending a clinic for ASD (N = 31) were evaluated. No association was observed between ID and the severity of autistic symptoms, developmental level and behavioral problems. ID was detected in 32.3% (N = 10) of the children based on serum ferritin level. In this study, the negative impact of low serum ferritin in ASD has not been confirmed. On the other hand, the rate of ID was considerably high in this sample of children with ASD compared to normative data of preschool children. Further studies with larger samples are needed to clarify the relationship between ID and clinical variables associated with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2009.12.008 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=102 [article] Iron deficiency in preschool children with autistic spectrum disorders [texte imprimé] / Ayhan BILGIC, Auteur ; C. Kağan GURKAN, Auteur ; Serhat TURKOGLU, Auteur ; Ömer Faruk AKCA, Auteur ; Birim Günay KILIÇ, Auteur ; Runa USLU, Auteur . - 2010 . - p.639-644. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 4-4 (October-December 2010) . - p.639-644 Mots-clés : Iron-deficiency Ferritin Autistic-spectrum-disorders Preschool-children Behavioral-problems Index. décimale : PER Périodiques Résumé : Iron deficiency (ID) cause negative outcomes on psychomotor and behavioral development of infants and young children. Children with autistic spectrum disorders (ASD) are under risk for ID and this condition may increase the severity of psychomotor and behavioral problems, some of which already inherently exist in these children. In the present study, the frequency of ID and the association between ID and autistic symptoms, developmental level, and behavioral problems in preschool children attending a clinic for ASD (N = 31) were evaluated. No association was observed between ID and the severity of autistic symptoms, developmental level and behavioral problems. ID was detected in 32.3% (N = 10) of the children based on serum ferritin level. In this study, the negative impact of low serum ferritin in ASD has not been confirmed. On the other hand, the rate of ID was considerably high in this sample of children with ASD compared to normative data of preschool children. Further studies with larger samples are needed to clarify the relationship between ID and clinical variables associated with ASD. En ligne : http://dx.doi.org/10.1016/j.rasd.2009.12.008 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=102

Serum vitamin D and folate levels in children with autism spectrum disorders / ÇaÄŸatay UÄžUR in Research in Autism Spectrum Disorders, 8-12 (December 2014)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 8-12 (December 2014) . - p.1641-1647 Titre : Serum vitamin D and folate levels in children with autism spectrum disorders Type de document : texte imprimé Auteurs : ÇaÄŸatay UÄžUR, Auteur ; C. Kağan GURKAN, Auteur Article en page(s) : p.1641-1647 Langues : Anglais (eng) Mots-clés : Autism spectrum disorders  Vitamin D  Calcium  Folate Index. décimale : PER Périodiques Résumé : Abstract It has recently proposed that vitamin D and folate may be involved in the aetiology of autism. We investigated the serum levels of vitamin D, calcium (Ca), phosphorus (P), alkaline phosphatase (ALP) and folate in 54 young children, aged 3–8 years, with autism spectrum disorders (ASD) and in 54 age and gender matched normal controls. Vitamin D, Ca, P, ALP and folate levels in children with ASD were not different from control group. The correlational analysis in children with ASD revealed that Aberrant Behaviour Checklist, Autism Behaviour Checklist, and Childhood Autism Rating Scale scores and the level of cognitive development were not correlated with these laboratory findings. Our findings do not support the idea that serum levels of vitamin D and folate might be low in children with ASD. Nevertheless, it is possible that vitamin D and folate deficiency may be playing a role in development of ASD at earlier ages or during prenatal period. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.09.002 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243 [article] Serum vitamin D and folate levels in children with autism spectrum disorders [texte imprimé] / ÇaÄŸatay UÄžUR, Auteur ; C. Kağan GURKAN, Auteur . - p.1641-1647. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 8-12 (December 2014) . - p.1641-1647 Mots-clés : Autism spectrum disorders  Vitamin D  Calcium  Folate Index. décimale : PER Périodiques Résumé : Abstract It has recently proposed that vitamin D and folate may be involved in the aetiology of autism. We investigated the serum levels of vitamin D, calcium (Ca), phosphorus (P), alkaline phosphatase (ALP) and folate in 54 young children, aged 3–8 years, with autism spectrum disorders (ASD) and in 54 age and gender matched normal controls. Vitamin D, Ca, P, ALP and folate levels in children with ASD were not different from control group. The correlational analysis in children with ASD revealed that Aberrant Behaviour Checklist, Autism Behaviour Checklist, and Childhood Autism Rating Scale scores and the level of cognitive development were not correlated with these laboratory findings. Our findings do not support the idea that serum levels of vitamin D and folate might be low in children with ASD. Nevertheless, it is possible that vitamin D and folate deficiency may be playing a role in development of ASD at earlier ages or during prenatal period. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.09.002 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=243

Targeted treatments in autism and fragile X syndrome / C. Kağan GURKAN in Research in Autism Spectrum Disorders, 6-4 (October-December 2012)  

Public ISBD [article]  inResearch in Autism Spectrum Disorders > 6-4 (October-December 2012) . - p.1311-1320 Titre : Targeted treatments in autism and fragile X syndrome Type de document : texte imprimé Auteurs : C. Kağan GURKAN, Auteur ; Randi J. HAGERMAN, Auteur Année de publication : 2012 Article en page(s) : p.1311-1320 Langues : Anglais (eng) Mots-clés : Fragile X syndrome  Autism  mGluR  GABA  Treatment Index. décimale : PER Périodiques Résumé : Autism is a neurodevelopmental disorder consisting of a constellation of symptoms that sometimes occur as part of a complex disorder characterized by impairments in social interaction, communication and behavioral domains. It is a highly disabling disorder and there is a need for treatment targeting the core symptoms. Although autism is accepted as highly heritable, there is no genetic cure at this time. Autism is shown to be linked to several genes and is a feature of some complex genetic disorders, including fragile X syndrome (FXS), fragile X premutation involvement, tuberous sclerosis and Rett syndrome. The term autism spectrum disorders (ASDs) covers autism, Asperger syndrome and pervasive developmental disorders (PDD-NOS) and the etiologies are heterogeneous. In recent years, targeted treatments have been developed for several disorders that have a known specific genetic cause leading to autism. Since there are significant molecular and neurobiological overlaps among disorders, targeted treatments developed for a specific disorder may be helpful in ASD of unknown etiology. Examples of this are two drug classes developed to treat FXS, Arbaclofen, a GABAB agonist, and mGluR5 antagonists, and both may be helpful in autism without FXS. The mGluR5 antagonists are also likely to have a benefit in the aging problems of fragile X premutation carriers, the fragile X-associated tremor ataxia syndrome (FXTAS) and the Parkinsonism that can occur in aging patients with fragile X syndrome. Targeted treatments in FXS which has a well known genetic etiology may lead to new targeted treatments in autism. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.05.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=165 [article] Targeted treatments in autism and fragile X syndrome [texte imprimé] / C. Kağan GURKAN, Auteur ; Randi J. HAGERMAN, Auteur . - 2012 . - p.1311-1320. Langues : Anglais (eng) in Research in Autism Spectrum Disorders > 6-4 (October-December 2012) . - p.1311-1320 Mots-clés : Fragile X syndrome  Autism  mGluR  GABA  Treatment Index. décimale : PER Périodiques Résumé : Autism is a neurodevelopmental disorder consisting of a constellation of symptoms that sometimes occur as part of a complex disorder characterized by impairments in social interaction, communication and behavioral domains. It is a highly disabling disorder and there is a need for treatment targeting the core symptoms. Although autism is accepted as highly heritable, there is no genetic cure at this time. Autism is shown to be linked to several genes and is a feature of some complex genetic disorders, including fragile X syndrome (FXS), fragile X premutation involvement, tuberous sclerosis and Rett syndrome. The term autism spectrum disorders (ASDs) covers autism, Asperger syndrome and pervasive developmental disorders (PDD-NOS) and the etiologies are heterogeneous. In recent years, targeted treatments have been developed for several disorders that have a known specific genetic cause leading to autism. Since there are significant molecular and neurobiological overlaps among disorders, targeted treatments developed for a specific disorder may be helpful in ASD of unknown etiology. Examples of this are two drug classes developed to treat FXS, Arbaclofen, a GABAB agonist, and mGluR5 antagonists, and both may be helpful in autism without FXS. The mGluR5 antagonists are also likely to have a benefit in the aging problems of fragile X premutation carriers, the fragile X-associated tremor ataxia syndrome (FXTAS) and the Parkinsonism that can occur in aging patients with fragile X syndrome. Targeted treatments in FXS which has a well known genetic etiology may lead to new targeted treatments in autism. En ligne : http://dx.doi.org/10.1016/j.rasd.2012.05.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=165

---

1 (1 - 3 / 3) Par page : 25 50 100 200